Free shipping on all orders over $ 500


Cat. No. M1512
Nimotuzumab Structure

CAS# 780758-10-3

Size Price Availability Quantity
1mg USD 600  USD600 In stock
5mg USD 1700  USD1700 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >98%
  • COA
  • MSDS
Biological Activity

Nimotuzumab (Nimotuzumab) is the first humanized monoclonal antibody targeting epidermal growth factor receptor (EGFR). Nimotuzumab has cytolytic effects on target tumors through its ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). EGFR is overexpressed in a variety of solid tumors, such as head and neck cancer, lung cancer and colorectal cancer. EGFR overexpression is highly associated with high aggressiveness, high metastasis, and poor prognosis. Nimotuzumab can competitively bind EGFR and block downstream signal transduction pathway mediated by EGFR, thereby inhibiting tumor cell proliferation, inducing differentiation, promoting apoptosis and inhibiting tumor angiogenesis. Nimotuzumab failed to recognize mouse EGFR.

Another CAS# 780758-10-3

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 147656.97
Formula C6566H10082N1746O2056S40
CAS Number 828933-51-3
Purity >98%
Storage -80°C for long term

[1] Ramakrishnan MS, et al. MAbs. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin.

Related EGFR/HER2 Products

Tesevatinib (XL-647; EXEL-7647; KD-019) is an orally available, multi-target tyrosine kinase inhibitor; inhibits EGFR, ErbB2, KDR, Flt4 and EphB4 kinase with IC50s of 0.3, 16, 1.5, 8.7, and 1.4 nM.

Tucatinib hemiethanolate

Tucatinib (Irbinitinib) hemiethanolate is a potent, orally active and selective HER2 inhibitor with an IC50 of 8 nM.


Tephrosin is a natural rotenoid which has potent antitumor activities. Tephrosin induces degradation of of EGFR and ErbB2 by inducing internalization of the receptors.

Pyrotinib dimaleate

Pyrotinib dimaleate (SHR-1258 dimaleate) is a potent and selective EGFR/HER2 dual inhibitor with IC50s of 13 and 38 nM, respectively.

Naquotinib mesylate

Naquotinib mesylate (ASP8273 mesylate) is an orally available, mutant-selective and irreversible EGFR inhibitor; with IC50s of 8-33 nM toward EGFR mutants and 230 nM for EGFR.

Abmole Inhibitor Catalog

Keywords: Nimotuzumab, CAS# 780758-10-3 supplier, EGFR/HER2, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.